Temasek Life Sciences Laboratory Limited

National Institute of Health Research and Development (Nihrd)-Ministry of Health of the Republic of Indonesia

Hwei-Sing Jimmy Kwang

Fang He

Hong Liang Qian

Prabakaran Mookkan

Siti Fadilah Supari

Nayana Prabhu Padubidhri

Sumathy Velumani

Jue Liu

Anbu Kumar Karuppannan

Rajesh Kumar Subaschandrabose

Isabelle Gek Joo Chen

Adeline Hui Ling Lau

Premanand Balraj

Hui Kheng Chua

Jennifer Siew Kee Lau

An expression cassette, wherein said expression cassette comprises: (a) an ie 1 promoter from white spot syndrome virus or a variant thereof; (b) a nucleic acid sequence encoding an N-terminal gp64 signal peptide or variant thereof, a nucleic acid sequence encoding an antigenic peptide, a nucleic acid encoding a transmembrane region, and a nucleic acid encoding a gp64 cytoplasmic region or variant thereof; in which the promoter is operably linked to the nucleic acid sequence.

Expression cassette for efficient surface display of antigenic proteins

The present invention relates to a monovalent H5N1 vaccine. More specifically, the present invention relates to the development of a monovalent H5 vaccine strain using hemagglutinin (HA) engineering to elicit cross-clade protection. The present invention also relates to an epitope-chimeric H5 and to a reverse genetics (RG) influenza virus expressing the epitope-chimeric H5.

Monovalent H5 vaccine

The present invention relates to the murine monoclonal antibody (mAb) 11B9 and to mAb 62 each of which target major neutralizing epitopes of influenza A H7 hemagglutinin and active fragments thereof. The present invention also relates to methods and compositions for the prophylaxis and treatment of H7 influenza using murine mAb 11B9, mAb 62 or fragments thereof. The present invention further relates to methods and kits for determining, identifying and/or quantifying (a) influenza A hemagglutinin in a sample or vaccine or (b) an antibody against influenza A hemagglutinin.

Monoclonal antibodies targeting neutralizing epitopes on H7 influenza viruses

The present invention relates to a universal H5N1 vaccine. More specifically, the present invention relates to the identification of three H5N1 strains which cover the entire variants in the neutralizing epitopes of hemagglutinin among most H5N1 lineages. The present invention further relates a universal H5N1 vaccine that comprises the three H5N1 strains or that comprises hemagglutinin peptides of each of these three strains.

Universal vaccine against H5N1 lineages

The present invention is based on the ORF3 gene of Porcine Circovirus Type 2 (PCV2) and the identification of tis apoptotic role. This discovery has led to the development of an attenuated live vaccine against PCV2.

Porcine circovirus type 2 vaccines

Monoclonal antibodies and related binding proteins that are specific for conformational epitopes of avian influenza virus H5 subtype hemagglutinin glycoprotein are provided. The antibodies can be used for the detection and treatment of H5 subtype AIV in specimens.

Monoclonal antibodies specific to hemagglutinin from influenza virus H5-subtype and uses thereof

The present invention relates to the murine monoclonal antibody 4C2 or to chimeric or humanized monoclonal antibodies specific to a major neutralizing epitope of influenza H5 hemagglutinin and active fragments thereof. The present invention also relates to methods and compositions for the prophylaxis and treatment of H5N1 influenza using such murine or chimeric or humanized monoclonal antibodies or fragments thereof.

Monoclonal antibody specific to major neutralizing epitope of influenza H5 hemagglutinin

Monoclonal antibodies and related binding proteins specific to influenza H5 subtype HA protein can be used in serological diagnosis of influenza H5 infection in mammalian and avian serum samples, including human serum samples. Each antibody reacts strongly with a wide variety of strains of H5 subtype and does not show cross-reactivity with non-H5 influenza subtypes.

Binding protein and epitope-blocking ELISA for the universal detection of H5-subtype influenza viruses

Monoclonal antibodies and related binding proteins that bind specifically to the envelope glycoprotein of H5 subtypes or neuraminidase glycoprotein of N1 subtypes of avian influenza virus (AIV) are provided. The monoclonal antibodies and related binding proteins are useful for the detection of H5 and N1 subtypes of AIV, including H5N1 subtypes and provide means for the diagnosis, surveillance and treatment of dangerous viral infections.

Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus H5-subtype or N1-subtype and uses thereof

This invention relates to methods and products for the diagnosis, surveillance, prevention, and treatment of influenza A virus infections in animals and humans. More particularly, the invention relates to antibodies and related binding proteins for the detection, prevention and treatment of influenza A viruses. The monoclonal antibodies and related binding proteins of the invention are useful for the treatment of the highly pathogenic H5 subtypes of avian influenza virus (AIV).

Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza A viruses and uses thereof

Continuous cell lines that are highly permissive to infection by porcine circovirus type 2 ('PCV2') are described. PCV2 is the causal agent of post-weaning multi-systemic wasting syndrome ('PMWS') in pigs. PMWS has emerged as a major disease that poses a significant threat to the economics of global swine industry. The highly permissive cell lines of this invention provide efficient and reliable sources of PCV2 for use in development of vaccines, therapies and diagnostic agents for PMWS.

Production of homogeneous cell line highly permissive to porcine circovirus type 2 (PCV2) infection

Monoclonal antibodies and related binding proteins that are specific for conformational epitopes of avian influenza virus K5 subtype hemagglutinin glycoprotein are provided. The antibodies can be used for the detection and treatment of H5 subtype AIV in specimens.

Growing community of inventors

Singapore, Singapore

Hwei-Sing Jimmy Kwang